Amikacin

Y. Vivian Tsai, Pharm.D., Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Taylor Imburgia, PharmD, BCPPS

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
    • Adjunctive prophylaxis with aerosolized amikacin has demonstrated some benefits in preventing ventilator-associated pneumonia in ICU patients.
    • Adjunctive therapy with aerosolized amikacin has not been proven to provide additional benefits in comparison to standard-of-care intravenous therapy alone.
  • Tuberculosis
  • Non-tubercular mycobacterial (NTM) infections, MAI
  • Nocardia
  • Aerosolized amikacin has been used for the management of cystic fibrosis exacerbations.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2024